xenograft model antitumor assays

Summary

Summary: In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.

Top Publications

  1. doi NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    Violeta Serra
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer Res 68:8022-30. 2008
  2. ncbi Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
    John M L Ebos
    Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
    Cancer Cell 15:232-9. 2009
  3. ncbi Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion
    Akira Orimo
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Cell 121:335-48. 2005
  4. pmc Guidelines for the welfare and use of animals in cancer research
    P Workman
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 102:1555-77. 2010
  5. ncbi BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Scott M Wilhelm
    Bayer Pharmaceuticals Corporation, West Haven, Connecticut 06516, USA
    Cancer Res 64:7099-109. 2004
  6. doi RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
    Georgia Hatzivassiliou
    Genentech, South San Francisco, California 94080, USA
    Nature 464:431-5. 2010
  7. pmc ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
    Christophe Ginestier
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
    Cell Stem Cell 1:555-67. 2007
  8. doi Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
    Sauveur Michel Maira
    Oncology Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH4002 Basel, Switzerland
    Mol Cancer Ther 7:1851-63. 2008
  9. pmc BRAF mutation predicts sensitivity to MEK inhibition
    David B Solit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Nature 439:358-62. 2006
  10. pmc Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission
    Heather A Hirsch
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School and Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02115, USA
    Cancer Res 69:7507-11. 2009

Detail Information

Publications296 found, 100 shown here

  1. doi NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    Violeta Serra
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer Res 68:8022-30. 2008
    ..In summary, NVP-BEZ235 inhibits the PI3K/mTOR axis and results in antiproliferative and antitumoral activity in cancer cells with both wild-type and mutated p110-alpha...
  2. ncbi Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
    John M L Ebos
    Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
    Cancer Cell 15:232-9. 2009
    ....
  3. ncbi Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion
    Akira Orimo
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Cell 121:335-48. 2005
    ..Our findings indicate that fibroblasts within invasive breast carcinomas contribute to tumor promotion in large part through the secretion of SDF-1...
  4. pmc Guidelines for the welfare and use of animals in cancer research
    P Workman
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 102:1555-77. 2010
    ....
  5. ncbi BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Scott M Wilhelm
    Bayer Pharmaceuticals Corporation, West Haven, Connecticut 06516, USA
    Cancer Res 64:7099-109. 2004
    ..These data demonstrate that BAY 43-9006 is a novel dual action RAF kinase and VEGFR inhibitor that targets tumor cell proliferation and tumor angiogenesis...
  6. doi RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
    Georgia Hatzivassiliou
    Genentech, South San Francisco, California 94080, USA
    Nature 464:431-5. 2010
    ..Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors...
  7. pmc ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
    Christophe Ginestier
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
    Cell Stem Cell 1:555-67. 2007
    ..These findings offer an important new tool for the study of normal and malignant breast stem cells and facilitate the clinical application of stem cell concepts...
  8. doi Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
    Sauveur Michel Maira
    Oncology Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH4002 Basel, Switzerland
    Mol Cancer Ther 7:1851-63. 2008
    ..Collectively, the preclinical data show that NVP-BEZ235 is a potent dual PI3K/mTOR modulator with favorable pharmaceutical properties. NVP-BEZ235 is currently in phase I clinical trials...
  9. pmc BRAF mutation predicts sensitivity to MEK inhibition
    David B Solit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Nature 439:358-62. 2006
    ..These data suggest an exquisite dependency on MEK activity in BRAF mutant tumours, and offer a rational therapeutic strategy for this genetically defined tumour subtype...
  10. pmc Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission
    Heather A Hirsch
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School and Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02115, USA
    Cancer Res 69:7507-11. 2009
    ....
  11. ncbi Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47. 2002
    ..Many elements of the hypoxia-response pathway are therefore good candidates for therapeutic targeting...
  12. doi In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models
    Klaus P Hoeflich
    Translational Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 15:4649-64. 2009
    ..We investigated the role of mitogen-activated protein kinase kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) inhibitors as targeted therapies for basal-like breast cancer...
  13. doi CD133 expression defines a tumor initiating cell population in primary human ovarian cancer
    Michael D Curley
    Vincent Center for Reproductive Biology, Vincent Obstetrics and Gynecology Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Stem Cells 27:2875-83. 2009
    ..Our data indicate that CD133 expression defines a NOD/SCID tumor initiating subpopulation of cells in human ovarian cancer that may be an important target for new chemotherapeutic strategies aimed at eliminating ovarian cancer...
  14. doi Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4
    Matilde Todaro
    Department of Surgical and Oncological Sciences, Cellular and Molecular Pathophysiology Laboratory, University of Palermo, 90127 Palermo, Italy
    Cell Stem Cell 1:389-402. 2007
    ..Our data suggest that colon tumor growth is dictated by stem-like cells that are treatment resistant due to the autocrine production of IL-4...
  15. ncbi AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical
    Barry R Davies
    Cancer and Infection Research Area, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
    Mol Cancer Ther 6:2209-19. 2007
    ..Moreover, enhanced antitumor efficacy can be obtained by combining AZD6244 with the cytotoxic drugs irinotecan or docetaxel...
  16. ncbi Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter
    David Dingli
    Molecular Medicine Program, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Blood 103:1641-6. 2004
    ..Testing in other radiosensitive cancers is warranted...
  17. pmc Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors
    Sudhakar Chintharlapalli
    Department of Veterinary Physiology and Pharmacology, Texas A and M University, College Station, TX 77843, USA
    BMC Cancer 11:371. 2011
    ....
  18. ncbi YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts
    Takahito Nakahara
    Institute for Drug Discovery Research, Astellas Pharma Inc, Tsukuba shi, Ibaraki, Japan
    Cancer Res 67:8014-21. 2007
    ..Further extensive investigation of YM155 in many types of cancer, including HRPC, seems to be worthwhile to develop this novel therapeutic approach...
  19. ncbi Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses
    Svetlana Komarova
    Division of Human Gene Therapy, Department of Medicine, Gene Therapy Center, University of Alabama at Birmingham, 901 19th Street South, BMR2 572, Birmingham, AL 35294 3300, USA
    Mol Cancer Ther 5:755-66. 2006
    ..These data show that MPCs can serve as intermediate carriers for replicative adenoviruses and suggest that the natural homing properties of specific cell types can be used for targeted delivery of these virions...
  20. pmc Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types
    Dimitrios Iliopoulos
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
    Cancer Res 71:3196-201. 2011
    ....
  21. doi Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth
    Guilherme Z Rocha
    Departments of Internal Medicine and Clinical Pathology, FCM, Universidade Estadual de Campinas UNICAMP, Campinas, SP, Brazil
    Clin Cancer Res 17:3993-4005. 2011
    ..Chemotherapy produces genotoxic stress and induces p53 activity, which can cross-talk with AMPK/mTOR pathway. Herein, we investigate whether the combination of metformin and paclitaxel has an effect in cancer cell lines...
  22. ncbi Cancer and the chemokine network
    Fran Balkwill
    Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary s Medical School, Charterhouse Square, London EC1M 6BQ, UK
    Nat Rev Cancer 4:540-50. 2004
  23. doi Novel therapies for metastatic castrate-resistant prostate cancer
    Farshid Dayyani
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Natl Cancer Inst 103:1665-75. 2011
    ..The rationale to disrupt this "two-compartment" crosstalk has led to the development of drugs that target tumor stromal elements in addition to the cancer epithelial cell...
  24. pmc Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma
    Dan Huang
    Laboratory of Cancer Genetics, Laboratory of Computational Biology, Van Andel Research Institute, Grand Rapids, Michigan 49503, USA
    Cancer Res 70:1063-71. 2010
    ..Our results reveal IL-8 as an important contributor to sunitinib resistance in ccRCC and a candidate therapeutic target to reverse acquired or intrinsic resistance to sunitinib in this malignancy...
  25. doi Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity
    Dharmalingam Subramaniam
    Section of Digestive Diseases and Nutrition, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73126, USA
    Cancer Res 68:1962-9. 2008
    ..Taken together, these data suggest that the novel curcumin-related compound EF24 is a potent antitumor agent that induces caspase-mediated apoptosis during mitosis and has significant therapeutic potential for gastrointestinal cancers...
  26. doi RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models
    Hong Yang
    Discovery Oncology, Hoffmann La Roche, Inc, Nutley, New Jersey, USA
    Cancer Res 70:5518-27. 2010
    ..There was no toxicity observed in any dose group in any of the in vivo models tested. Our findings offer evidence of the potent antitumor activity of RG7204 against melanomas harboring the mutant BRAF(V600E) gene...
  27. pmc Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance
    Nathan T Ihle
    M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 69:143-50. 2009
    ....
  28. ncbi Regulation of androgen receptor activity by tyrosine phosphorylation
    Zhiyong Guo
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Cancer Cell 10:309-19. 2006
    ....
  29. pmc Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche
    Janine T Erler
    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Cancer Cell 15:35-44. 2009
    ..CD11b+ cells and LOX also colocalize in biopsies of human metastases. Our findings demonstrate a critical role for LOX in premetastatic niche formation and support targeting LOX for the treatment and prevention of metastatic disease...
  30. ncbi ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models
    Cherrie K Donawho
    Abbott Laboratories, Abbott Park, Illinois 60064 6074, USA
    Clin Cancer Res 13:2728-37. 2007
    ..To evaluate the preclinical pharmacokinetics and antitumor efficacy of a novel orally bioavailable poly(ADP-ribose) polymerase (PARP) inhibitor, ABT-888...
  31. ncbi Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus
    Qian Zhang
    Genelux Corporation, San Diego Science Center, San Diego, California 92109, USA
    Cancer Res 67:10038-46. 2007
    ..These findings suggest that immune activation may combine with viral oncolysis to induce tumor eradication in this model, providing a novel perspective for the design of oncolytic viral therapies for human cancers...
  32. ncbi Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases
    Frank Winkler
    E L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Cancer Cell 6:553-63. 2004
    ..During the normalization window, but not before or after it, VEGFR2 blockade increases pericyte coverage of brain tumor vessels via upregulation of Ang1 and degrades their pathologically thick basement membrane via MMP activation...
  33. pmc Thioaptamer conjugated liposomes for tumor vasculature targeting
    Aman P Mann
    Department of Nanomedicine, University of Texas Health Science Center at Houston, 1825 Hermann Pressler, Houston, Texas 77030, USA
    Oncotarget 2:298-304. 2011
    ....
  34. ncbi Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products
    Ajaikumar B Kunnumakkara
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 67:3853-61. 2007
    ..018 versus control). Overall, our results suggest that curcumin potentiates the antitumor effects of gemcitabine in pancreatic cancer by suppressing proliferation, angiogenesis, NF-kappaB, and NF-kappaB-regulated gene products...
  35. pmc Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer
    Michael Graham Espey
    Molecular and Clinical Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Free Radic Biol Med 50:1610-9. 2011
    ..These data support the testing of pharmacologic ascorbate in adjunctive treatments for cancers prone to high failure rates with conventional therapeutic regimens, such as pancreatic cancer...
  36. pmc Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells
    Cristian Bellodi
    University of Leicester, United Kingdom
    J Clin Invest 119:1109-23. 2009
    ..Together, these findings suggest that autophagy inhibitors may enhance the therapeutic effects of TKIs in the treatment of CML...
  37. doi Mediating tumor targeting efficiency of nanoparticles through design
    Steven D Perrault
    Institute of Biomaterials and Biomedical Engineering, Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, 160 College Street, Toronto, ON, M5S 3E1, Canada
    Nano Lett 9:1909-15. 2009
    ..Our results provide design parameters for engineering nanoparticles for optimized tumor targeting of contrast agents and therapeutics...
  38. pmc Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
    Anthony C Faber
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA
    Proc Natl Acad Sci U S A 106:19503-8. 2009
    ..These data indicate simultaneous inhibition of PI3K-mTOR and MEK signaling is an effective strategy for treating EGFR mutant lung cancers, including those with acquired resistance to EGFR TKIs...
  39. pmc Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation
    Indira Jutooru
    Department of Veterinary Physiology and Pharmacology, Texas A and M University, College Station, Texas 77843, USA
    J Biol Chem 285:25332-44. 2010
    ....
  40. pmc Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action
    Wei Wang
    Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, and Comprehensive Cancer Center, University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL 35294, USA
    Cancer Lett 278:241-8. 2009
    ..The data presented here support further evaluation of the ginsenosides for pancreatic cancer therapy...
  41. ncbi FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma
    Qing Liu
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 16:3182-92. 2010
    ..Because of the absence of curative therapy for MCL, we explored FTY720 as a novel agent against MCL...
  42. doi Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model
    Achuthamangalam B Madhankumar
    Department of Neurosurgery H110, G M Leader Family Laboratory, Penn State University, College of Medicine, M S Hershey Medical Center, 500 University Drive, Hershey, PA 17033 0850, USA
    Mol Cancer Ther 8:648-54. 2009
    ..These data show that IL-13 targeted nanovesicles are a viable option for the treatment of brain tumors...
  43. pmc High-resolution imaging of the dynamic tumor cell vascular interface in transparent zebrafish
    Konstantin Stoletov
    Department of Pathology and Moores Cancer Center, University of California at San Diego, 9500 Gilman Drive, MC0612, La Jolla, CA 92093, USA
    Proc Natl Acad Sci U S A 104:17406-11. 2007
    ..Zebrafish could also provide a cost-effective means for the rapid development of therapeutic agents directed at blocking human cancer progression and tumor-induced angiogenesis...
  44. doi Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models
    Alberto Gabizon
    Experimental Oncology Laboratory, Shaare Zedek Medical Center, 11 Shmuel Bayit Street, 7th Floor, PO Box 3235, Jerusalem 91031, Israel
    Cancer Chemother Pharmacol 66:43-52. 2010
    ..Targeting liposomes to the FR has been proposed as a way to enhance the effects of liposome-based chemotherapy...
  45. doi FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1
    Dmitri Pchejetski
    Department of Surgery and Cancer, Imperial College London, London, United Kingdom
    Cancer Res 70:8651-61. 2010
    ..Our findings suggest that low, well-tolerated doses of FTY720 could offer significant improvement to the clinical treatment of prostate cancer...
  46. pmc Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo
    Jieru Meng
    Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    PLoS ONE 5:e14124. 2010
    ..Our study suggests that the combination of AZD6244 and MK2206 has a significant synergistic effect on tumor growth in vitro and in vivo and leads to increased survival rates in mice bearing highly aggressive human lung tumors...
  47. doi Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation
    Kuen Feng Chen
    Department of Medical Research, National Taiwan University Hospital, Taiwan
    J Hepatol 52:88-95. 2010
    ..Previously we reported that Akt inactivation determines the sensitivity of hepatocellular carcinoma (HCC) cells to bortezomib. Here we report that combined treatment with sorafenib and bortezomib shows synergistic effects in HCC...
  48. pmc Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
    Florence I Raynaud
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK
    Mol Cancer Ther 8:1725-38. 2009
    ..Together, these data support the development of GDC-0941 as a potent, orally bioavailable inhibitor of phosphatidylinositide 3-kinase. GDC-0941 has recently entered phase I clinical trials...
  49. ncbi Intraperitoneal therapy of ovarian cancer using an engineered measles virus
    Kah Whye Peng
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 62:4656-62. 2002
    ..Trackable recombinant measles viruses warrant further investigation for therapy of ovarian cancer...
  50. doi Blocking neuropilin-2 function inhibits tumor cell metastasis
    Maresa Caunt
    Tumor Biology and Angiogenesis, Genentech, Inc, South San Francisco, CA 94080, USA
    Cancer Cell 13:331-42. 2008
    ..Our results demonstrate that Nrp2, which was originally identified as an axon-guidance receptor, is an attractive target for modulating metastasis...
  51. pmc Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance
    George N Naumov
    Children s Hospital, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, and Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Clin Cancer Res 15:3484-94. 2009
    ..EGFR TKI resistance is not completely understood and has been associated with certain EGFR and K-RAS mutations and MET amplification...
  52. ncbi Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
    Tammie C Yeh
    Array BioPharma, Inc, Boulder, Colorado 80301, USA
    Clin Cancer Res 13:1576-83. 2007
    ..We have developed a highly potent and selective inhibitor of MEK1/2. The purpose of these studies has been to show the biological efficacy of ARRY-142886 (AZD6244) in enzymatic, cellular, and animal models...
  53. pmc Choosing the right cell line for breast cancer research
    Deborah L Holliday
    Leeds Institute of Molecular Medicine, University of Leeds, Leeds LS9 7TF, UK
    Breast Cancer Res 13:215. 2011
    ....
  54. ncbi Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells
    Kuen Feng Chen
    Department of Medical Research, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei
    Cancer Res 68:6698-707. 2008
    ..Targeting Akt signaling overcomes drug resistance to bortezomib in HCC cells, which provides a new approach for the combinational therapy of HCC...
  55. doi Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays
    Mark G Manfredi
    Millennium Pharmaceuticals, Inc, Cambridge, 40 Landsdowne Street, Cambridge, MA 02139, USA
    Clin Cancer Res 17:7614-24. 2011
    ..Here, we describe preclinical characterization of alisertib (MLN8237), a selective AAK inhibitor, incorporating these novel pharmacodynamic assays...
  56. ncbi Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model
    Serk In Park
    The Program in Cancer Biology, Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, TX 77030, USA
    Cancer Res 68:3323-33. 2008
    ..Therefore, we conclude that SFKs are promising therapeutic targets for treatment of human prostate cancer and that Src and Lyn activities affect different cellular functions required for prostate tumor growth and progression...
  57. pmc Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways
    Tingfang Yi
    Center for Cancer and Stem Cell Biology, Institute for Bioscience and Technology, Texas A and M University System Health Science Center, 2121 West Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 7:1789-96. 2008
    ..Overall, our results indicate that thymoquinone inhibits tumor angiogenesis and tumor growth and could be used as a potential drug candidate for cancer therapy...
  58. doi YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model
    Takahito Nakahara
    Institute for Drug Discovery Research, Astellas Pharma Inc, Tsukuba shi, Ibaraki, Japan
    Anticancer Drugs 22:454-62. 2011
    ....
  59. ncbi Contributions of human tumor xenografts to anticancer drug development
    Edward A Sausville
    Marlene and Stewart Greenebaum Cancer Center, and Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, 22 S Greene Street, Baltimore, MD 21201, USA
    Cancer Res 66:3351-4, discussion 3354. 2006
    ....
  60. doi Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models
    Takahito Nakahara
    Institute for Drug Discovery Research, Astellas Pharma, Inc, Tsukuba, Ibaraki, Japan
    Cancer Sci 102:614-21. 2011
    ..The broad and potent antitumor activity presented in the present study is indicative of the therapeutic potential of YM155 in the clinical setting...
  61. doi YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer
    Kentaro Yamanaka
    Drug Discovery Research, Astellas Pharma Inc, 21 Miyukigaoka, Tsukuba, Ibaraki 305 8585, Japan
    Int J Oncol 39:569-75. 2011
    ..These results suggest that the survivin-suppressing activity of YM155 may offer a novel therapeutic option for patients with metastatic TNBC...
  62. ncbi CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells
    Claudia M Kowolik
    Divisions of Molecular Medicine, Beckman Research Institute and City of Hope National Medical Center, Duarte, California, USA
    Cancer Res 66:10995-1004. 2006
    ..These data imply that modifications to the CAR can result in improved therapeutic potential of CD19-specific T cells expressing this second-generation CAR...
  63. pmc Therapeutic potential of AZD1480 for the treatment of human glioblastoma
    Braden C McFarland
    Department of Cell Biology, 1918 University Blvd, MCLM 313, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Mol Cancer Ther 10:2384-93. 2011
    ....
  64. doi Indirubin inhibits tumor growth by antitumor angiogenesis via blocking VEGFR2-mediated JAK/STAT3 signaling in endothelial cell
    Xiaoli Zhang
    Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
    Int J Cancer 129:2502-11. 2011
    ..Our study provided the first evidence for antitumor angiogenesis activity of indirubin and the related molecular mechanism. Our investigations suggested that indirubin was a potential drug candidate for angiogenesis related diseases...
  65. pmc Oncolytic vaccinia therapy of squamous cell carcinoma
    Zhenkun Yu
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mol Cancer 8:45. 2009
    ..We examined the therapeutic effects of an attenuated, replication-competent vaccinia virus (GLV-1h68) as an oncolytic agent against a panel of six human head and neck SCC cell lines...
  66. doi Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts
    Christina L Roland
    Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390 8593, USA
    Mol Cancer Ther 8:1761-71. 2009
    ..These findings further define the complex molecular interactions in the tumor microenvironment and provide a translational tool that may be relevant to the treatment of breast cancer...
  67. doi Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent
    I Gentschev
    Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA
    Cancer Gene Ther 16:320-8. 2009
    ..This is the first report demonstrating that vaccinia virus is an effective tool for the therapy of canine mammary cancers, which might next be applied to dogs with breast tumors...
  68. pmc Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
    Jing Qing
    Department of Molecular Oncology, Genentech Inc, South San Francisco, California, USA
    J Clin Invest 119:1216-29. 2009
    ..These studies provide in vivo evidence demonstrating an oncogenic role of FGFR3 in bladder cancer and support antibody-based targeting of FGFR3 in hematologic and epithelial cancers driven by WT or mutant FGFR3...
  69. pmc Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo
    Madeleine S Q Kortenhorst
    Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, James Buchanan Brady Urological Institute, School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA
    Mol Cancer Ther 8:802-8. 2009
    ..Therefore, nuclear structural alterations may serve as a biomarker for histone deacetylase inhibitor treatment...
  70. pmc Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma
    Randall W Alfano
    Cancer Research Institute, Scott and White Memorial Hospital, Temple, Texas 76502, USA
    Mol Cancer Ther 9:190-201. 2010
    ..Therefore, the MMP-activated LeTx could be used not only in the clinical management of V600E B-Raf ATC but potentially in any solid tumor...
  71. doi Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model
    Puja Sapra
    Enzon Pharmaceuticals, Inc, Piscataway, New Jersey 08854, USA
    Clin Cancer Res 14:1888-96. 2008
    ..We have developed a novel polymer-drug conjugate, EZN-2208, made by linking SN38 with a multiarm polyethylene glycol via a glycine linker...
  72. doi Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer
    Xiong Cai
    Curis Inc, 45 Moulton Street, Cambridge, Massachusetts 02138, USA
    J Med Chem 53:2000-9. 2010
    ....
  73. doi DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity
    Rachelle S Singleton
    Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand
    Cancer Res 69:3884-91. 2009
    ....
  74. pmc Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program
    Peter J Houghton
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Pediatr Blood Cancer 54:921-6. 2010
    ..IMC-A12 is a fully human IgG1 antibody that prevents ligand binding to the IGF-1R...
  75. pmc Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation
    Xuerong Wang
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Cancer Res 68:7409-18. 2008
    ..Consequently, the sustained Akt activation during mTOR inhibition will counteract the anticancer efficacy of the mTOR inhibitors...
  76. pmc Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β-galactosidase-activatable prodrug seco-analog of duocarmycin SA
    C M Seubert
    Department of Biochemistry, University of Wurzburg, Germany
    Cancer Gene Ther 18:42-52. 2011
    ..Moreover, in vivo, additional prodrug treatment had beneficial effects on tumor regression in GLV-1h68-treated GI-101A-xenografted mice...
  77. ncbi Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging
    Christian R Schnell
    Oncology Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Cancer Res 68:6598-607. 2008
    ....
  78. pmc Atg5 regulates phenethyl isothiocyanate-induced autophagic and apoptotic cell death in human prostate cancer cells
    Ajay Bommareddy
    Department of Pharmacology and Chemical Biology, and University of Pittsburgh Cancer Institute, Pennsylvania, USA
    Cancer Res 69:3704-12. 2009
    ..In conclusion, the present study indicates that Atg5 plays an important role in regulation of PEITC-induced autophagic and apoptotic cell death...
  79. doi Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235
    Douglas W McMillin
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 69:5835-42. 2009
    ..g., dexamethasone and doxorubicin) or novel (e.g., bortezomib) anti-MM agents showed lack of antagonism. These results indicate that BEZ235 merits clinical testing, alone and in combination with other agents, in MM...
  80. pmc Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity
    Nripen Chanda
    Department of Radiology, Harry S Truman Veterans Administration Medical Center, Columbia, MO, USA
    Proc Natl Acad Sci U S A 107:8760-5. 2010
    ....
  81. doi Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo
    Hua Chen
    The Hepatosplenic Surgery Center, Department of General Surgery, The First Clinical Medical School of Harbin Medical University, Harbin, China
    Anticancer Drugs 20:131-40. 2009
    ..This study indicates that DHA may be a potent and promising agent to combat pancreatic cancer...
  82. ncbi Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action
    Junmei Hou
    Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences Graduate School of the Chinese Academy of Sciences, Shanghai 200031, People s Republic of China
    Clin Cancer Res 14:5519-30. 2008
    ..However, the mechanisms underlying these activities remain unclear. This study was designed to determine their antitumor efficacy and underlying mechanisms of action in human hepatoma cells...
  83. pmc A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
    Michael M Schmidt
    Department of Biological Engineering, Massachusetts Institute of Technology, Building E19 551, 50 Ames Street, Cambridge, MA 02139, USA
    Mol Cancer Ther 8:2861-71. 2009
    ..All model predictions are shown to be consistent with experimental observations from published targeting studies. The results and techniques have implications for drug development, imaging, and therapeutic dosing...
  84. ncbi Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer
    Jeroen T Buijs
    Department of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands
    Cancer Res 67:8742-51. 2007
    ..Because exogenous BMP7 can still counteract the breast cancer growth at the primary site and in bone, BMP7 may represent a novel therapeutic molecule for repression of local and bone metastatic growth of breast cancer...
  85. pmc Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68
    Yong A Yu
    Genelux Corporation, San Diego Science Center, 3030 Bunker Hill Street, Suite 310, San Diego, CA 92109, USA
    Mol Cancer Ther 8:141-51. 2009
    ..In conclusion, the GLV-1h68 strain showed outstanding therapeutic effects and a documented safety profile in mice, with great promise for future clinical development...
  86. pmc Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma
    Zhengyu Li
    Department of Gynecology and Obstetrics, West China Second corrected Hospital, Sichuan University, Chengdu 610041, China
    Mol Cell Proteomics 7:1810-23. 2008
    ..01) and the inhibition of tumor growth in vivo (p < 0.01). These data suggest that cyclophilin A may serve as a novel prognostic factor and possibly an attractive therapeutic target for endometrial carcinoma...
  87. pmc Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer
    Yun Su
    Department of Surgery, Zhongda Hospital, The School of Clinical Medicine, Southeast University, Nanjing, China
    Cancer Epidemiol Biomarkers Prev 19:327-37. 2010
    ..ALDH1A1 may serve as a useful marker for monitoring the progression of bladder tumor and identifying bladder cancer patients with poor prognosis who might benefit from adjuvant and effective treatments...
  88. pmc Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy
    Jyotsnabaran Halder
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 12:4916-24. 2006
    ..Based on encouraging in vitro results with FAK silencing, we examined the in vivo therapeutic potential of this approach using short interfering RNA (siRNA) in the neutral liposome 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC)...
  89. ncbi Hyaluronan: from extracellular glue to pericellular cue
    Bryan P Toole
    Department of Cell Biology and Anatomy, Medical University of South Carolina, 173 Ashley Avenue, Charleston, South Carolina 29425, USA
    Nat Rev Cancer 4:528-39. 2004
  90. ncbi Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo
    Yihong Zhang
    Department of Oncology Research, Amgen, Inc, Thousand Oaks, California 91320, USA
    Cancer Res 68:6680-7. 2008
    ....
  91. pmc Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells
    Vinata B Lokeshwar
    Division of Urology Research, Department of Urology M 800, University of Miami Miller School of Medicine, P O Box 016960, Miami, FL 33101, USA
    Cancer Res 70:2613-23. 2010
    ..Therefore, the anticancer effects of 4-MU, an orally bioavailable and relatively nontoxic agent, are primarily mediated by inhibition of HA signaling...
  92. ncbi Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers
    Iduna Fichtner
    Max Delbruck Center for Molecular Medicine, Berlin Buch, Germany
    Clin Cancer Res 14:6456-68. 2008
    ..It was the aim of our study to establish an extensive panel of non-small cell lung cancer (NSCLC) xenograft models useful for the testing of novel compounds and for the identification of biomarkers...
  93. pmc A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity
    John E Weldon
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 4264, USA
    Blood 113:3792-800. 2009
    ..We conclude that HA22-LR advances the therapeutic efficacy of HA22 by using an approach that may be applicable to other PE-based immunotoxins...
  94. pmc Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68
    Ivaylo Gentschev
    Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA
    J Biomed Biotechnol 2010:489759. 2010
    ..Our data documented that the GLV-1h68 virus has a great potential for treatment of human prostate carcinoma...
  95. doi Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma
    Meike Vogler
    University Children s Hospital, Ulm University, Ulm, Germany
    Cancer Res 69:2425-34. 2009
    ..These findings build the rationale for further (pre)clinical development of XIAP inhibitors and TRAIL against pancreatic cancer...
  96. pmc In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762
    James B Mitchell
    Radiation Biology and Radiation Oncology Branches, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Cancer Res 16:2076-84. 2010
    ..A novel checkpoint kinase 1/2 inhibitor, AZD7762, was evaluated for potential enhancement of radiosensitivity for human tumor cells in vitro and in vivo xenografts...
  97. pmc Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity
    Cory Allen
    Molecular Medicine Department, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Mol Ther 16:1556-64. 2008
    ..Strains of measles virus retargeted against the glioma-specific IL-13Ralpha2 receptor have comparable therapeutic efficacy, and improved specificity as compared with the unmodified measles virus strain MV-GFP in vitro and in vivo...
  98. pmc FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism
    Andrea Valentine
    School of Pharmacy, Queen s University Belfast, Belfast, United Kingdom
    Clin Cancer Res 17:1044-56. 2011
    ..Antiangiogenic therapies can be an important adjunct to the management of many malignancies. Here we investigated a novel protein, FKBPL, and peptide derivative for their antiangiogenic activity and mechanism of action...
  99. doi The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models
    Mark J Williamson
    Millennium Pharmaceuticals, Cambridge, MA 02139, USA
    Mol Cancer Ther 8:3234-43. 2009
    ....
  100. pmc Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations
    Georgia Konstantinidou
    Division of Hematology and Oncology, Simmons Comprehensive Cancer Center, and Hamon Center for Therapeutic Oncology Research, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas TX 75390, USA
    Cancer Res 69:7644-52. 2009
    ..These findings may have general applicability in cancer therapy, because aberrant activation of PI3K occurs frequently in human cancer...
  101. doi Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice
    Sharmila Shankar
    Department of Biochemistry, Center for Biomedical Research, The University of Texas Health Science Center at Tyler, 11937 U S Highway 271, Tyler, TX 75708 3154, USA
    Mol Cancer Ther 8:1596-605. 2009
    ..In conclusion, sequential treatment with SAHA followed by TRAIL may target multiple pathways in tumor progression, angiogenesis, and metastasis and represents a novel therapeutic approach to treat breast cancer...

Research Grants190 found, 100 shown here

  1. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter Houghton; Fiscal Year: 2008
    ..The studies have the potential to radically alter outcome for these children, and reduce the debilitating sequellae of high dose radiation and chemotherapy. ..
  2. RAPAMYCIN INDUCED SELECTIVE APOPTOSIS IN MALIGNANT CELLS
    Peter Houghton; Fiscal Year: 1999
    ..The long-term goal of these studies is to develop alternative curative therapy for children with cancer that will avoid the often devastating events, associated with contemporary intensive chemo-radiotherapy regimens. ..
  3. MTOR as a Therapeutic Target in Childhood Cancer
    Peter Houghton; Fiscal Year: 2004
    ..abstract_text> ..
  4. MTOR as a Therapeutic Target in Childhood Cancer
    Peter Houghton; Fiscal Year: 2003
    ..abstract_text> ..
  5. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter Houghton; Fiscal Year: 2005
    ..e. p53 or p21Cip1. Our studies will develop the biochemical framework to underpin a novel approach by which rapamycins can induce tumor-selective cytotoxicity based on the loss of the tumor suppressor p53. ..
  6. RAPAMYCIN INDUCED SELECTIVE APOPTOSIS IN MALIGNANT CELLS
    Peter Houghton; Fiscal Year: 2001
    ..The long-term goal of these studies is to develop alternative curative therapy for children with cancer that will avoid the often devastating events, associated with contemporary intensive chemo-radiotherapy regimens. ..
  7. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter Houghton; Fiscal Year: 2006
    ..e. p53 or p21Cip1. Our studies will develop the biochemical framework to underpin a novel approach by which rapamycins can induce tumor-selective cytotoxicity based on the loss of the tumor suppressor p53. ..
  8. RAPAMYCIN INDUCED SELECTIVE APOPTOSIS IN MALIGNANT CELLS
    Peter Houghton; Fiscal Year: 2000
    ..The long-term goal of these studies is to develop alternative curative therapy for children with cancer that will avoid the often devastating events, associated with contemporary intensive chemo-radiotherapy regimens. ..
  9. MTOR as a Therapeutic Target in Childhood Cancer
    Peter Houghton; Fiscal Year: 2005
    ..abstract_text> ..
  10. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter J Houghton; Fiscal Year: 2010
    ..The studies have the potential to radically alter outcome for these children, and reduce the debilitating sequellae of high dose radiation and chemotherapy. ..
  11. RAPAMYCIN INDUCED SELECTIVE APOPTOSIS IN MALIGNANT CELLS
    Peter Houghton; Fiscal Year: 2002
    ..The long-term goal of these studies is to develop alternative curative therapy for children with cancer that will avoid the often devastating events, associated with contemporary intensive chemo-radiotherapy regimens. ..
  12. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter Houghton; Fiscal Year: 2003
    ..e. p53 or p21Cip1. Our studies will develop the biochemical framework to underpin a novel approach by which rapamycins can induce tumor-selective cytotoxicity based on the loss of the tumor suppressor p53. ..
  13. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter Houghton; Fiscal Year: 2004
    ..e. p53 or p21Cip1. Our studies will develop the biochemical framework to underpin a novel approach by which rapamycins can induce tumor-selective cytotoxicity based on the loss of the tumor suppressor p53. ..
  14. MTOR as a Therapeutic Target in Childhood Cancer
    Peter Houghton; Fiscal Year: 2002
    ..abstract_text> ..
  15. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter Houghton; Fiscal Year: 2009
    ..The studies have the potential to radically alter outcome for these children, and reduce the debilitating sequellae of high dose radiation and chemotherapy. ..
  16. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter Houghton; Fiscal Year: 2007
    ..e. p53 or p21Cip1. Our studies will develop the biochemical framework to underpin a novel approach by which rapamycins can induce tumor-selective cytotoxicity based on the loss of the tumor suppressor p53. ..
  17. ENHANCING RADIATION THERAPY: VASCULAR TARGETING AGENTS
    Dietmar Siemann; Fiscal Year: 2004
    ....
  18. ENHANCING RADIATION THERAPY: VASCULAR TARGETING AGENTS
    Dietmar W Siemann; Fiscal Year: 2010
    ..Experiments are designed to investigate how to deliver such therapies for maximum antitumor efficacy as well as determining the potential of developing predictive indicators of their treatment response. ..
  19. Combining Anti-Angiogenesis Strategies and Radiotherapy
    Dietmar W Siemann; Fiscal Year: 2010
    ..Experiments are designed to investigate the mechanisms underlying the interaction between such therapies and to develop approaches that would maximize the anti-tumor efficacy of such combined treatments. ..
  20. RADIATION AND DRUG EFFECTS ON TUMOR CELL SUBPOPULATIONS
    Dietmar Siemann; Fiscal Year: 2001
    ..Ultimately we hope that these approaches can be reliably developed to an extent where the use of human tumor biopsy material may lead to radiotherapy treatments more tailored to the individual patient. ..
  21. Radioimmunotherapy of CD20+ Lymphomas & CD45+Leukemias
    JOHN PAGEL; Fiscal Year: 2008
    ..abstract_text> ..
  22. Combining Anti Angiogenesis Strategies and Radiotherapy
    Dietmar Siemann; Fiscal Year: 2005
    ..We believe that these studies will provide essential insights into the therapeutic utility of employing antiangiogenic treatment strategies as adjuvants to radiotherapy. ..
  23. ENHANCING RADIATION THERAPY: VASCULAR TARGETING AGENTS
    Dietmar Siemann; Fiscal Year: 2005
    ....
  24. Combining Anti Angiogenesis Strategies and Radiotherapy
    Dietmar Siemann; Fiscal Year: 2001
    ..We believe that these studies will provide essential insights into the therapeutic utility of employing antiangiogenic treatment strategies as adjuvants to radiotherapy. ..
  25. Combining Anti Angiogenesis Strategies and Radiotherapy
    Dietmar Siemann; Fiscal Year: 2002
    ..We believe that these studies will provide essential insights into the therapeutic utility of employing antiangiogenic treatment strategies as adjuvants to radiotherapy. ..
  26. Combining Anti Angiogenesis Strategies and Radiotherapy
    Dietmar Siemann; Fiscal Year: 2004
    ..We believe that these studies will provide essential insights into the therapeutic utility of employing antiangiogenic treatment strategies as adjuvants to radiotherapy. ..
  27. ENHANCING RADIATION THERAPY: VASCULAR TARGETING AGENTS
    Dietmar Siemann; Fiscal Year: 2009
    ..Experiments are designed to investigate how to deliver such therapies for maximum antitumor efficacy as well as determining the potential of developing predictive indicators of their treatment response. ..
  28. Combining Anti Angiogenesis Strategies and Radiotherapy
    Dietmar Siemann; Fiscal Year: 2003
    ..We believe that these studies will provide essential insights into the therapeutic utility of employing antiangiogenic treatment strategies as adjuvants to radiotherapy. ..
  29. RADIATION AND DRUG EFFECTS ON TUMOR CELL SUBPOPULATIONS
    Dietmar Siemann; Fiscal Year: 2000
    ..Ultimately we hope that these approaches can be reliably developed to an extent where the use of human tumor biopsy material may lead to radiotherapy treatments more tailored to the individual patient. ..
  30. ENHANCING RADIATION THERAPY: VASCULAR TARGETING AGENTS
    Dietmar Siemann; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  31. Combining Anti-Angiogenesis Strategies and Radiotherapy
    Dietmar Siemann; Fiscal Year: 2008
    ..Experiments are designed to investigate the mechanisms underlying the interaction between such therapies and to develop approaches that would maximize the anti-tumor efficacy of such combined treatments. ..
  32. Combining Anti-Angiogenesis Strategies and Radiotherapy
    Dietmar Siemann; Fiscal Year: 2009
    ..Experiments are designed to investigate the mechanisms underlying the interaction between such therapies and to develop approaches that would maximize the anti-tumor efficacy of such combined treatments. ..
  33. Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot
    John M Pagel; Fiscal Year: 2010
    ..We anticipate that these approaches will cure more patients and cause fewer toxicities than currently available therapies. ..
  34. RADIATION AND DRUG EFFECTS ON TUMOR CELL SUBPOPULATIONS
    Dietmar Siemann; Fiscal Year: 1999
    ..Ultimately we hope that these approaches can be reliably developed to an extent where the use of human tumor biopsy material may lead to radiotherapy treatments more tailored to the individual patient. ..
  35. ENHANCING RADIATION THERAPY: VASCULAR TARGETING AGENTS
    Dietmar Siemann; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  36. ENHANCING ACTIVITY OF ALKYLATING AGENTS IN NEUROBLASTOMA
    Charles Reynolds; Fiscal Year: 2006
    ....
  37. ENHANCING ACTIVITY OF ALKYLATING AGENTS IN NEUROBLASTOMA
    Charles Reynolds; Fiscal Year: 2008
    ....
  38. ENHANCING ACTIVITY OF ALKYLATING AGENTS IN NEUROBLASTOMA
    Charles Reynolds; Fiscal Year: 2000
    ..TdT-labeling/flow cytometry and caspase activation. We anticipate that this research will contribute to the understanding of alkylator resistance in neuroblastoma and will result in more effective treatment modalities. ..
  39. ANTIFOLATE RESISTANCE OSTEOSARCOMA
    Richard Gorlick; Fiscal Year: 2001
    ..These studies may define the incidence of intrinsic and acquired methotrexate resistance in tumor samples and suggest the use of new antifolates and therapeutic strategies in the treatment of osteosarcoma. ..
  40. Targeting of the Androgen Receptor in Prostate Cancer
    John Isaacs; Fiscal Year: 2002
    ..These peptide prodrugs will be designed so that they are substrates for the enzymatic activity of either Prostate Specific Antigen. ..
  41. Targeting of the Androgen Receptor in Prostate Cancer
    John Isaacs; Fiscal Year: 2005
    ..These peptide prodrugs will be designed so that they are substrates for the enzymatic activity of either Prostate Specific Antigen. ..
  42. ENHANCING ACTIVITY OF ALKYLATING AGENTS IN NEUROBLASTOMA
    Charles Reynolds; Fiscal Year: 2007
    ....
  43. Antifolate Resistance in Osteosarcoma
    Richard Gorlick; Fiscal Year: 2006
    ....
  44. Targeting of the Androgen Receptor in Prostate Cancer
    John Isaacs; Fiscal Year: 2003
    ..These peptide prodrugs will be designed so that they are substrates for the enzymatic activity of either Prostate Specific Antigen. ..
  45. ENHANCING ACTIVITY OF ALKYLATING AGENTS IN NEUROBLASTOMA
    Charles Reynolds; Fiscal Year: 2009
    ....
  46. ENHANCING ACTIVITY OF ALKYLATING AGENTS IN NEUROBLASTOMA
    CHARLES PATRICK REYNOLDS; Fiscal Year: 2010
    ....
  47. ENHANCING ACTIVITY OF ALKYLATING AGENTS IN NEUROBLASTOMA
    Charles Reynolds; Fiscal Year: 2001
    ..TdT-labeling/flow cytometry and caspase activation. We anticipate that this research will contribute to the understanding of alkylator resistance in neuroblastoma and will result in more effective treatment modalities. ..
  48. Antifolate Resistance in Osteosarcoma
    Richard Gorlick; Fiscal Year: 2005
    ....
  49. Targeting of the Androgen Receptor in Prostate Cancer
    John Isaacs; Fiscal Year: 2004
    ..These peptide prodrugs will be designed so that they are substrates for the enzymatic activity of either Prostate Specific Antigen. ..
  50. Antifolate Resistance in Osteosarcoma
    Richard Gorlick; Fiscal Year: 2007
    ....
  51. ANTIFOLATE RESISTANCE OSTEOSARCOMA
    Richard Gorlick; Fiscal Year: 2000
    ..These studies may define the incidence of intrinsic and acquired methotrexate resistance in tumor samples and suggest the use of new antifolates and therapeutic strategies in the treatment of osteosarcoma. ..
  52. Antifolate Resistance in Osteosarcoma
    Richard Gorlick; Fiscal Year: 2004
    ....
  53. ANTIFOLATE RESISTANCE OSTEOSARCOMA
    Richard Gorlick; Fiscal Year: 1999
    ..These studies may define the incidence of intrinsic and acquired methotrexate resistance in tumor samples and suggest the use of new antifolates and therapeutic strategies in the treatment of osteosarcoma. ..
  54. CELL/CELL INTERACTION AND PROSTATE GROWTH
    John Isaacs; Fiscal Year: 1999
    ....
  55. CELL/CELL INTERACTION AND PROSTATE GROWTH
    John Isaacs; Fiscal Year: 2000
    ....
  56. Significance of Genetic Alterations in Neuroblastoma
    John Maris; Fiscal Year: 2005
    ..It is expected that these will be of prognostic importance and serve as specific targets for developmental therapeutics. ..
  57. Bispecific Antibody Pretargeted Therapy of Pancreatic Cancer
    ROBERT SHARKEY; Fiscal Year: 2006
    ..Overall, these studies will assist in establishing whether this type of pretargeting approach could have a role in the clinical management of pancreatic cancer. [unreadable] [unreadable] [unreadable]..
  58. Bispecific Antibody Pretargeted Therapy of Pancreatic Cancer
    ROBERT SHARKEY; Fiscal Year: 2007
    ..Overall, these studies will assist in establishing whether this type of pretargeting approach could have a role in the clinical management of pancreatic cancer. [unreadable] [unreadable] [unreadable]..
  59. COORDINATED REGULATION OF ANTIOXIDANT ENZYMES
    Michael Kelner; Fiscal Year: 2005
    ..abstract_text> ..
  60. THE ROLE OF HORMONES IN HEALTH AND DISEASE
    WILLIAM NORTH; Fiscal Year: 2008
    ..The ETP also provides a center for improved teaching and health delivery for Northern New England. ..
  61. Minimal-disease radioimmunotherapy of colorectal cancer
    Serengulam Govindan; Fiscal Year: 2003
    ..Successful feasibility study will lead to extended preclinical therapy studies and the initiation of a clinical Phase I RAIT trial in a SBIR Phase II program. ..
  62. Halogenated Alkenes and Microsomal GSH-transferases
    Michael Kelner; Fiscal Year: 2006
    ..4] To determine the relative contribution of MGST1 and MGST2 to cellular antioxidant capacity through studies utilizing human MGST1 and MGST2 null cells. ..
  63. MAb-based targeted chemotherapy of lung cancer
    Serengulam Govindan; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  64. An anti-CD74 MAb-drug conjugate for B-cell malignancies
    Serengulam Govindan; Fiscal Year: 2008
    ..The goal of the proposed project is to develop a safer and a more efficacious targeted chemotherapy of MM using a unique tumor-selective antibody, which can complement or augment existing therapies. ..
  65. COORDINATED REGULATION OF ANTIOXIDANT ENZYMES
    Michael Kelner; Fiscal Year: 2004
    ..abstract_text> ..
  66. COORDINATED REGULATION OF ANTIOXIDANT ENZYMES
    Michael Kelner; Fiscal Year: 1992
    ..The second portion of the project will examine the effect of modifying anti-oxidant enzymes, again through introduction of sense or anti-sense expression vectors, on the life span of these fibroblasts...
  67. Halogenated Alkenes and Microsomal GSH-transferases
    Michael Kelner; Fiscal Year: 2009
    ..4] To determine the relative contribution of MGST1 and MGST2 to cellular antioxidant capacity through studies utilizing human MGST1 and MGST2 null cells. ..
  68. GRSA Proteins in the Diagnosis of Breast Cancer
    WILLIAM NORTH; Fiscal Year: 2002
    ..These methods could be applicable to all patients with breast cancer or suspected breast cancer. ..
  69. Significance of Genetic Alterations in Neuroblastoma
    John Maris; Fiscal Year: 2002
    ..It is expected that these will be of prognostic importance and serve as specific targets for developmental therapeutics. ..
  70. Calcitonin in Prostate Growth and Neoplasia
    Girish Shah; Fiscal Year: 2008
    ..abstract_text> ..
  71. Improved Detection of Cancer Using Bi Specific Antibody
    ROBERT SHARKEY; Fiscal Year: 2001
    ....
  72. INVESTIGATION INTO PARAQUAT CYTOTOXICITY
    Michael Kelner; Fiscal Year: 1993
    ..The mechanism and cellular level (DNA, RNA, protein synthesis) by which this cell continues to express glutathione peroxidase, even when exposed to paraquat, will be determined...
  73. INVESTIGATION INTO PARAQUAT CYTOTOXICITY
    Michael Kelner; Fiscal Year: 1992
    ..The mechanism and cellular level (DNA, RNA, protein synthesis) by which this cell continues to express glutathione peroxidase, even when exposed to paraquat, will be determined...
  74. GPX1 ENZYME REGULATION BY OXIDATIVE XENOBIOTICS
    Michael Kelner; Fiscal Year: 2001
    ..These studies will provide critical information regarding cellular response to oxidative stress and aid in determining if a common regulatory mechanism exists for GSH-dependent enzymes. ..
  75. Calcitonin in Prostate Growth and Neoplasia
    Girish Shah; Fiscal Year: 2001
    ..The proposed studies will define the role for prostatic CT in regulation of growth and differentiation in malignant human prostate gland. ..
  76. Targets of Immune-Mediated Tumor Destruction
    Glenn Dranoff; Fiscal Year: 2006
    ..Determine whether vaccination with the murine homologs of these antigens can stimulate protective immunity against challenge with murine melanoma cells. ..
  77. Bispecific Antibody Pretargeting for Therapy
    ROBERT SHARKEY; Fiscal Year: 2006
    ..Anti-antibody responses will also be measured to the humanized bsMAb. This clinical trial will be conducted at the Fox Chase Cancer Center. [unreadable] [unreadable]..
  78. Focal Adhesion Kinase-Tumor Biology and Therapeutics
    William Cance; Fiscal Year: 2005
    ..By defining the mechanism of interaction between FAK and its critical binding partners, we will identify novel sites for molecular targeting to induce apoptosis in human breast cancer cells. ..
  79. High Grade Astrocytoma Specific Molecular Targeting
    Waldemar Debinski; Fiscal Year: 2002
    ....
  80. In Vivo Efficacy of Multi-Targeted Androgen Inhibition as Prostate Cancer Therapy
    Elahe Mostaghel; Fiscal Year: 2008
    ....
  81. NEUROPEPTIDES AND SMALL CELL CARCINOMA
    WILLIAM NORTH; Fiscal Year: 2000
    ..The information obtained is expected to result in effective chemotherapeutic and immunotherapeutic interventions for all patients with limited and extensive SCCL. ..
  82. Dynamic regulation of MT1-MMP at the tumor cell surface and malignancy
    Rafael Fridman; Fiscal Year: 2007
    ..The results of this application will contribute to our understanding of MT1-MMP function in tumor cells and contribute to the collective effort aimed at inhibiting its activity in cancerous tissues. [unreadable] [unreadable]..
  83. Tea Polyphenols in Chemoprevention of Prostate Cancer
    SUSANNE MARGARETE HENNING; Fiscal Year: 2010
    ..The results will assist in designing dietary supplements for chemoprevention of early stages of prostate cancer or during watchful waiting. ..
  84. Molecular Requirements for Recombinant Cytotoxins Efficacy
    Waldemar Debinski; Fiscal Year: 2010
    ..It is expected that the new information gathered will be invaluable in further molecular design of recombinant anti-cancer cytotoxins. ..
  85. CSF DEFICIENCY AND ANTITUMOR IMMUNITY
    Glenn Dranoff; Fiscal Year: 2000
    ..2. To evaluate the ability of GM-CSF and IL-3 deficient mice to process exogenous antigens for MHC class I presentation. 3. To evaluate the functions of GM-CSF and IL-3 in promising cancer vaccination strategies. ..
  86. THE ROLE OF HORMONES IN HEALTH AND DISEASE
    WILLIAM NORTH; Fiscal Year: 2007
    ..The ETP alsoprovides acenter for improved teaching and health delivery for Northern New England. ..
  87. SURFACE BINDING AND ACTIVATION OF MMP9 IN TUMOR CELLS
    Rafael Fridman; Fiscal Year: 1999
    ..The results of these studies will address a new paradigm in the regulation of proMMP-9 activation and may provide novel and specific tools to inhibit MMP-9 activity in human tumors. ..